Hematopoietic Cell Transplantation for Sickle Cell Disease
Children · 26.05.2026 · 13 (6) · 741
DOI: 10.3390/children13060741 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Children, online erschienen am 26.05.2026. Verfasst von Gregory Michael Taylor Guilcher. Beteiligte Einrichtung: Departments of Oncology and Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sickle cell disease is the most common monogenetic disease worldwide and affects millions of children and adults. While supportive care practices have improved life expectancy, particularly in high income countries, sickle cell disease typically has adverse impact on quality of life and reduced life expectancy. As a result, patients and providers are increasingly seeking information regarding curative and transformative therapies and advocating for improved global access. This review will describe allogeneic hematopoietic cell transplantation eligibility, approaches to transplant, short and long-term outcomes and key supportive care considerations for providers who care for patients with sickle cell disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Oncology and Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
ORCID-Profile: Gregory Michael Taylor Guilcher
Zitieren
APA
Guilcher, G. M. T. (2026). Hematopoietic Cell Transplantation for Sickle Cell Disease. Children, 13(6), 741. https://doi.org/10.3390/children13060741
Vancouver
Guilcher GMT. Hematopoietic Cell Transplantation for Sickle Cell Disease. Children. 2026;13(6):741. doi:10.3390/children13060741
BibTeX
@article{Guilcher2026,
author = {Guilcher, Gregory Michael Taylor},
title = {Hematopoietic Cell Transplantation for Sickle Cell Disease},
journal = {Children},
year = {2026},
volume = {13},
number = {6},
pages = {741},
doi = {10.3390/children13060741}
}
EUVIMED